Back to search results

Menopausal Hormone Therapy and Heart Function Study

This study is looking at how Menopausal Hormone Therapy (MHT) affects the heart's pumping ability, specifically the left ventricular stroke volume (the amount of blood your heart pumps with each beat). Researchers want to compare women who are using MHT with those who are not. You may be able to join if you are a woman between 45 and 60 years old and have not had certain heart conditions or entered menopause due to surgery or specific medications. The study aims to understand the difference in heart function between these groups. The study plans to enroll 50 participants, but its current status is unclear.

Study design
This is an observational study, meaning researchers will observe participants rather than assigning treatments. It plans to include 50 women.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Left ventricular stroke volume is measured at baseline (the start of the study). No further follow-up is specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07242391

Menopausal Hormone Therapy And Left Ventricular Function

Recruiting
Not specifiedAges 45–60Observational
Mayo Clinic
~50 participants
Updated 2026-08-27 on ClinicalTrials.gov
What's tested:Menopausal Hormone Therapy

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Left ventricular stroke volume
Measured over Baseline

Conditions

Menopause
Left Ventricular Dysfunction

Explore related trials

Left Ventricular DysfunctionMenopause present

Where it's being run

1 sites across 1 states
Minnesota1

Study leadership

  • Joshua Bock, Ph.D. · PRINCIPAL_INVESTIGATOR · Mayo Clinic

Who to contact

Joshua Bock, Ph.D.
[email protected]
507-422-0768
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

Male sex
Females between STRAW+10 stages -5 and 0
PMF in STRAW+10 stage +2
PMF using oral hormone therapy
Females who entered menopause due to a surgical procedure or in response to pharmacotherapy (e.g., gonadotrophin releasing hormone agonists or chemotherapy)
Heart disease such as hypertropic cardiomyopathy, congenital abnormalities, chronic heart failure, valve disease, and a history of myocardial infarction
Medications that impact the central nervous system including selective serotonin reuptake inhibitors, anxiolytics, sedatives, anticholinergic agents, dopamine, amphetamines, or wake-promoting agents (e.g., modafinil). Other medications will be evaluated on an individual basis by the PI.
Cardiovascular medications is also an exclusion criterion which includes those acting on the renin-angiotensin-aldosterone axis, adrenergic receptor antagonists, diuretics, nitrates, and calcium channel antagonists. Other medications will be evaluated on an individual basis by the PI.
Pregnancy
COPD
Diabetes
CKD
Raynaud's phenomenon
Sleep disorders
Shift workers
BMI ≥40.0kg/m2
Use of nicotine-containing products within the two years preceding study visits
Active cancer treatment

What this trial measures

  • Left ventricular stroke volumeBaseline

    Left ventricular stroke volume is the amount of blood pumped from the left ventricle per heartbeat (mL)